About this Research Topic
The role of gamma delta (γδ T) T cells in cancer cell-based immunotherapies is currently under investigation, but has not been fully elucidated. γδ T cells constitute 1-10% of total T cells subsets in the peripheral blood mononuclear cells (PBMCs).
The significance of using γδ T cells in cancer cell-based therapies is that unlike other T cells subsets (CD8+ T cells), the killing activity of γδ T cells is independent of MHC-class I- mediated antigen presentation. This characteristic of γδ T cells is like natural killer (NK) cells, and could help cancer patients who have defective NK cells.
The subject of this research topic focuses on strategies or methodologies established to prepare γδ T cells for cell-based cancer immunotherapies. This Research Topic solicits articles, review articles, commentaries, and perspectives in the areas of γδ T cells biology and novel expansion/proliferation methodologies and/or related fields that focus on presenting the significant role of γδ T cells as an effector component in the framework of cancer therapy. In addition, this topic will focus on completed or ongoing clinical trial studies and case reports of using γδ T cells as cancer cell-based therapeutics alone or in combination with other cancer therapies.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
The significance of using γδ T cells in cancer cell-based therapies is that unlike other T cells subsets (CD8+ T cells), the killing activity of γδ T cells is independent of MHC-class I- mediated antigen presentation. This characteristic of γδ T cells is like natural killer (NK) cells, and could help cancer patients who have defective NK cells.
The subject of this research topic focuses on strategies or methodologies established to prepare γδ T cells for cell-based cancer immunotherapies. This Research Topic solicits articles, review articles, commentaries, and perspectives in the areas of γδ T cells biology and novel expansion/proliferation methodologies and/or related fields that focus on presenting the significant role of γδ T cells as an effector component in the framework of cancer therapy. In addition, this topic will focus on completed or ongoing clinical trial studies and case reports of using γδ T cells as cancer cell-based therapeutics alone or in combination with other cancer therapies.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords: γδ T cells, cancer immunotherapy, T cells, advancement in γδ T cells-based cancer therapies, clinical trials, case reports
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
